Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Company codePBMWW
Company namePsyence Biomedical Ltd
IPO dateDec 10, 2021
Founded at2023
CEODr. Neil Maresky
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address121 Richmond Street West Penthouse
CityTORONTO
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeM5H 2K1
Phone17744604171
Website
Company codePBMWW
IPO dateDec 10, 2021
Founded at2023
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data